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Introduction {#sec1}
============

The abundance of a protein results from the interplay of epigenetic, (post-)transcriptional, and (post-)translational events. The post-transcriptional control of gene expression is based on the recruitment of RNA-binding proteins (RBP) ([@bib22]) to homing sequences on the target messenger RNA (mRNA) via RNA-recognition motifs ([@bib38]). Prominent mechanisms in that respect include micro RNA (miRNA) ([@bib5]) and AU-, U- or GU-rich elements mediating RNA decay ([@bib51]).

Contrary to miRNA-based regulation, AU-rich element (ARE)-based mechanisms do not require annealing of complementary RNA strands but a direct recruitment of RBP to the target transcript. These elements are preferentially localized in the 3′ untranslated region (3' UTR) of the mRNA. Initially, this mechanism was described only for the pentamer AUUUA, whereas later experimental evidence revealed that extended variants reaching up to 13-mers, as well as GU- and U-rich sequence patterns, were likewise able to modulate the half-life of transcripts ([@bib18]). Moreover, the impact of these elements on mRNA stability is determined by the nature of the recruited RBP, which can be grouped into mRNA stabilizers, such as *ELAVL1* ([@bib53]), *NCL* ([@bib48]), and *ZMAT3* ([@bib50]), or mRNA destabilizing members, such as *HNRNPD* ([@bib27]) and *ZFP36* ([@bib41]).

Although ARE-mediated mRNA modulation is known to influence the landscape of gene expression ([@bib2]), its impact on members of the BCL-2 family, which are key regulators of the intrinsic (mitochondrial) apoptotic pathway, is poorly understood, with the notable exception of BCL-2 itself. The expression of BCL-2 has been shown to be influenced by the balance of *HNRNPD* and *NCL* recruited to the 3' UTR of its transcript, with implications for the integrity of the mouse B cell compartment upon deletion of critical AREs therein ([@bib15], [@bib45]).

BCL-2-related ovarian killer (BOK) is a member of the BCL-2 family closely related to the pro-apoptotic multi-BH-domain containing members BAX and BAK ([@bib19], [@bib31], [@bib55]). Although BOK has a particularly high affinity for the ER and associated membranes, its enforced accumulation or overexpression leads to intrinsic apoptosis, suggesting that cellular BOK levels need to be tightly regulated in healthy cells ([@bib16], [@bib37], [@bib44]). Interestingly, there are indications of selective loss of BOK in cancer, as the genomic locus containing the human *BOK* gene is deleted in a substantial percentage (average 15%) of human cancers ([@bib4]). We recently showed that BOK is downregulated in patients with late stage (lymph node positive) versus early stage non-small cell lung cancer (NSCLC), with high BOK protein levels being predictive of extended patient survival ([@bib40]). Likewise, BOK was shown to be downregulated and of prognostic value in colorectal carcinoma ([@bib8]). Current understanding of the mechanism(s) regulating these changes in BOK abundance is meagre, restricted to epigenetic regulation by promoter methylation ([@bib40]) or selective proteasomal turnover, which seems to be linked to the localization of BOK at the ER and regulated by the ERAD pathway and the interaction of BOK with inositol triphosphate receptors ([@bib37], [@bib47], [@bib46]).

Tripartite Motif Containing 28 (TRIM28/TIF1-β/KAP1) is a co-repressor multidomain protein acting together with Krüppel-Associated Box Zinc Finger Protein (KRAB-ZNF) transcription factors ([@bib21], [@bib39]), nucleosome remodeling deacetylase (NuRD), and heterochromatin-associated protein 1 (HP1) ([@bib10]) to silence multiple genes at the chromatin level. These interactions sustain the role of TRIM28 as a regulatory hub in multiple processes such as the maintenance of cell stemness ([@bib25]), inhibition of p53 activity ([@bib42]), transcriptional repression ([@bib23]), and epithelial-mesenchymal transition (EMT) ([@bib49]). Interestingly, despite its key role in regulating chromatin activity ([@bib1]) and direct gene transcription ([@bib6]), TRIM28 lacks obvious DNA-binding domains and thus depends on adaptor proteins to localize to the DNA ([@bib28]). The functional pleiotropism of TRIM28 has been linked to tumorigenesis, and studies with human cancer cell lines or xenografts highlight the contribution of TRIM28 to sustained mTOR activation and cell cycle progression ([@bib33]), sustained Warburg effect ([@bib29]), and maintenance of the cancer stem cell niche ([@bib12]). Moreover, from a clinical perspective, TRIM28 has been reported to be overexpressed in cervical ([@bib33]), hepatocellular ([@bib29]), breast ([@bib12]), and ovarian ([@bib11]) cancers, in all of which it is associated with a poor clinical prognosis.

Here, we describe a regulatory circuit controlling BOK expression at the transcript level, involving conserved (AU/U)-rich elements (ARE/URE) present in the 3' UTRs of both human and mouse BOK mRNA. Remarkably, negative regulation of human *BOK* expression through mRNA destabilization depends on the unexpected association of TRIM28 with these URE sites. Furthermore, TRIM28-dependent repression specifically targets BOK, whereas it does not affect the pro-apoptotic multidomain BCL-2 family members BAX and BAK. This TRIM28-mediated negative regulation of BOK might have important clinical implications since *TRIM28*^high^*BOK*^low^ levels were associated with poor patient survival in certain cancer (sub-)types.

Results {#sec2}
=======

The 3′ Untranslated Region of Mouse *Bok* mRNA Contains a Strong Negative-Regulating AU-Rich Element {#sec2.1}
----------------------------------------------------------------------------------------------------

We noticed that the architecture of the mouse *Bok* mRNA dramatically influences protein expression levels upon transient transfection into the human embryonic kidney cell line HEK293T, which expresses barely detectable levels of endogenous BOK. To further study this phenomenon, we generated a series of expression constructs consisting of the *Bok* coding sequence (CDS) harboring permutations of the 5′ and 3′ UTR or truncated versions of the latter ([Figure 1](#fig1){ref-type="fig"}A). Although transfection of *Bok* CDS (or FLAG-tagged *Bok* CDS) resulted in strong protein expression, it was barely detectable when *Bok* cDNA was used ([Figure 1](#fig1){ref-type="fig"}B). This was an indication for the presence of one or more negative regulatory elements in either the 5' and/or the 3' UTR of *Bok* mRNA. As depicted in [Figure 1](#fig1){ref-type="fig"}C, the expression of *Bok* CDS containing either the 3' UTR or the 5' UTR demonstrated that it is the 3' UTR that is responsible for the observed repression.Figure 1Identification of a Negative Regulatory Element in the 3′ UTR of Mouse *Bok*(A--E) (A) List of constructs generated to narrow down the region containing destabilizing elements in the mouse *Bok* transcript sequence. Western blot analysis of BOK levels in total protein extracts prepared from HEK293T cells transiently transfected with (B) *Bok* cDNA or *Bok* CDS (with or without N-terminal FLAG tag), (C) *Bok* CDS with or without its 5' UTR and/or 3' UTR, (D) *Bok* CDS combined with the full length or truncated version of its 3' UTR, or (E) *Bok* CDS combined with its wild-type 3' UTR or harboring discrete point mutations in a predicted AU-rich element (ARE) therein. Each immunoblot is representative of at least three independent experiments. Tubulin and/or EGFP were used to normalize the transfection efficiency and gel loading. The double band detected for BOK corresponds to the full-length protein and a shorter version translated from a cryptic start codon at methionine 15 ([@bib46]). Bar graphs to the right of panels D and E show the quantification of BOK levels from quantitative immunoblots (using near-infrared fluorochromes) and real-time quantitative PCR. The data are presented as mean ± SD, N = 3. Statistical analysis was performed using a one-way ANOVA followed by a Tukey *post-hoc* test in GraphPad Prism. Significance levels, p \> 0.05^*ns*^, p \< 0.01\*\*, p \< 0.001\*\*\*.

To map the position of the regulatory sequence(s) present in the 3' UTR, we generated three deletion mutants of the mouse *Bok* CDS-3'UTR construct, in which similarly sized parts within the 3' UTR were removed (3' UTRΔ1, 183 bp; 3' UTRΔ2, 207 bp; and 3' UTRΔ3, 234 bp) ([Figure 1](#fig1){ref-type="fig"}A). Co-transfection of these mutants (together with pcDNA3/EGFP at a ratio of 1:10 for normalization of transfection efficiencies) into HEK293T cells and subsequent analyses by qPCR and western blotting demonstrated that region 1 (most proximal to the stop codon) contained all of the negative regulatory element(s) ([Figure 1](#fig1){ref-type="fig"}D). Furthermore, the concordance observed in [Figure 1](#fig1){ref-type="fig"}D (right panel) between transcript and protein levels indicated that the negative regulatory element likely affects *Bok* mRNA stability, resulting in its degradation.

We next made use of the AREsite2 prediction tool (<http://nibiru.tbi.univie.ac.at/AREsite2/>) ([@bib18]) to identify regulatory elements in the mouse *Bok* 3' UTR and found one sequence corresponding to an ARE located within the 3' UTR region 1 (position 1,049--1,053, sequence AUUUA) ([Figure 1](#fig1){ref-type="fig"}A). As shown in [Figure 1](#fig1){ref-type="fig"}E, site-directed mutagenesis of this ARE site (AUUUA -\> GACGU) restored both *Bok* mRNA and protein expression to levels comparable with expression of the CDS alone. Taken together, these data demonstrate that a single ARE site within the proximal region of the 3' UTR strongly compromises mouse *Bok* mRNA stability, resulting in decreased protein expression.

The Mouse *Bok* ARE Sequence Suppresses the Expression of Unrelated Coding Sequences {#sec2.2}
------------------------------------------------------------------------------------

Considering that the initial experiments were performed with mouse *Bok* expression constructs in a human cell line we next wanted to confirm our findings in an autologous cell model, namely, SV40 immortalized *Bok*^-/-^ mouse embryonic fibroblasts (MEF) ([@bib16]). Similar to HEK293T cells, transfection of the mouse *Bok* CDS into *Bok*^-/-^ MEFs resulted in a strong protein signal by western blotting, whereas it was barely detectable when the entire cDNA was transfected ([Figure 2](#fig2){ref-type="fig"}A). Mutation of the ARE site restored BOK protein levels to approximately 70% of the positive control, demonstrating that the ARE-mediated regulatory mechanism is functional in both human and mouse cells ([Figure 2](#fig2){ref-type="fig"}A). qPCR analysis confirmed that BOK protein levels correlated with mRNA levels ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Validation of Mouse BOK 3' UTR Regulatory Function in Autologous Cells and an Unrelated Coding Sequence(A) The functionality of the ARE-mediated regulation mechanism in autologous cells was evaluated at the protein and mRNA levels by transiently transfecting mouse *Bok* CDS, CDS-3'UTR, and CDS-3'UTR(AREmut) expression constructs into *Bok*^*−/−*^ SV40 MEF. Transfection efficiency was normalized to a co-transfected pcDNA3/EGFP vector.(B and C) (B) Expression of chimeric EGFP constructs flanked by mouse *Bok\'s* 5′ and 3′-UTR, with or without ARE-specific mutation, transiently transfected into HEK293T cells or (C) *Bok*^*−/−*^ SV40 MEF. The transfection efficiency was normalized to a co-transfected pcDNA3/FLAG-MCL-1 vector. The data of quantitative immunoblotting are presented as mean ± SD, N = 3.Statistical analysis was performed using a one-way ANOVA followed by a Tukey *post-hoc* test in GraphPad Prism. Significance levels, p \< 0.0001\*\*\*\*.

The previous results supported the existence of a conserved regulation of *Bok* expression through its 3' UTR. We next tested whether the 3' UTR could also modulate unrelated coding sequences. To this purpose, we evaluated the expression of enhanced green fluorescent protein (EGFP) flanked by the 5′ and 3′ UTRs of mouse *Bok*, with or without mutation of the ARE site. In line with our previous results, the inclusion of the *Bok* 3' UTR massively reduced EGFP expression in both HEK293T and *Bok*^*−/−*^ SV40 MEF, whereas the ARE mutation led to a significant rescue of EGFP levels ([Figures 2](#fig2){ref-type="fig"}B and 2C). These data indicate that the ARE sequence in the mouse *Bok* 3' UTR is a genuine repressor of gene expression irrespective of the upstream coding sequence.

The Human *BOK* 3' UTR Contains U-Rich Regulatory Elements {#sec2.3}
----------------------------------------------------------

Despite similar exon-intron organization of the mouse and human BOK genes, a remarkable difference resides in the lengths of their respective 3' UTRs, with the human 3' UTR being three times longer than its mouse counterpart; nevertheless, human *BOK* expression was also found to be strongly repressed by its 3' UTR ([Figure 3](#fig3){ref-type="fig"}A). Using *in silicio* tools described earlier, we screened for the existence of ARE sites in the human *BOK* 3' UTR, also including related GU/CU- and U-rich elements in the analysis. Contrary to the mouse transcript, the human 3' UTR lacks classical ARE sites (core sequence AUUUA) but contains six stretches of non-canonical U-rich elements (five URE, motifs W^1−2^UUUW^1−2^, and one AWTAAA motif, W=U/A) ([Figure S1](#mmc1){ref-type="supplementary-material"}). These six sequences overlapped to some degree and could be reduced to three potential U-rich elements we termed URE1, 2 and 3, respectively ([Figure 3](#fig3){ref-type="fig"}B). Site-directed mutagenesis of these sites showed that individual destruction of either URE1 or 2 partially recovered *BOK* mRNA and protein expression, whereas mutation of URE3 did not show any effect ([Figure 3](#fig3){ref-type="fig"}C). However, simultaneous mutation of URE1 and 2, or of all three URE sites (URE1-3), significantly recovered BOK expression to levels approaching those seen for the transfection control with the CDS ([Figure 3](#fig3){ref-type="fig"}C). These results indicate that the 3' UTR-dependent negative regulation of BOK is conserved between mice and humans. Furthermore, similar to the single destabilizing ARE site in the mouse *Bok* transcript, there are two U-rich elements (URE1 and 2) present in the human *BOK* 3' UTR exerting a comparable regulatory role.Figure 3Discovery of Analogous Negative Regulatory Elements in the 3' UTR of Human *BOK* Transcript(A) Transient transfection into HEK293T cells of human *BOK* CDS or its coding sequence fused to its 3' UTR, highlighting the occurrence of negative regulators in the 3' UTR.(B) List of constructs generated used to validate the functionality of the predicted U-rich destabilizing elements (URE) within the human *BOK* transcript sequence (see also [Figure S1](#mmc1){ref-type="supplementary-material"}).(C) Representative immunoblot showing BOK levels in HEK293T cells transiently transfected with the indicated human *BOK* expression constructs. The right panel shows the levels of BOK obtained from quantitative immunoblotting using near-infrared fluorochromes and real-time quantitative PCR quantification from three independent experiments. The data are presented as mean ± SD, N = 3.Statistical analysis was performed using a one-way ANOVA followed by a Tukey *post-hoc* test in GraphPad Prism. Significance levels, p \> 0.05^*ns*^, p \< 0.05\*, p \< 0.01\*\*, p \< 0.001\*\*\*.

Identification of URE-Binding Proteins in the 3' UTR of Human BOK by Proteomics Approaches {#sec2.4}
------------------------------------------------------------------------------------------

To identify proteins binding to the URE elements within the human *BOK* 3' UTR and being critical for its repression, we performed a protein pull-down from HEK293T-derived cell lysate using synthetic biotinylated RNA probes encoding human *BOK* CDS bearing the wild-type or the URE mutated (UREmut1-3) version of the 3' UTR, followed by identification by mass spectrometry. Initial analysis using silver staining on SDS-PAGE-separated samples already indicated differences in the protein binding to each probe compared with the beads-only negative control ([Figure 4](#fig4){ref-type="fig"}A). Overall, 749 hits were identified, of which 246 (33%) were unique to at least one of the three studied samples ([Figure 4](#fig4){ref-type="fig"}B and [Table S1](#mmc2){ref-type="supplementary-material"}). A total of 101 hits were overrepresented more than 1.5 times in the samples pulled down with the wild-type probe compared with the UREmut1-3 probe ([Figure 4](#fig4){ref-type="fig"}B). Additional filtering criteria using adjusted p values and false discovery rate led to a final list of 84 candidates that were clustered in three major categories according to the differential abundance among the probes and the background ([Figure 4](#fig4){ref-type="fig"}C). Of particular interest were the resulting hits in clusters 1 and 3, as they displayed the most dramatic differences between wild-type and UREmut1-3 probes; thus, candidates from these clusters were selected for the validation round. Furthermore, we performed an overrepresentation gene ontology test with the selected 106 candidates ([Figure 4](#fig4){ref-type="fig"}D) and found a significant enrichment in proteins involved in biological processes related to RNA metabolism, processing, and splicing. This group contained several proteins known to assemble into (macro)molecular complexes, which, surprisingly, are not only restricted to the above-mentioned splicing and mRNA 3'-end processing pathways, but also involved in DNA fragmentation during apoptosis, according to the annotation of the Reactome Pathway database ([@bib17]).Figure 4Identification of Proteins Binding to the UREs within the Human *BOK* 3' UTR(A and B) HEK293T lysates were incubated with biotinylated RNA probes encoding human *BOK* CDS-3'UTR or CDS-3'UTR(UREmut1-3), a version with the three predicted URE sites mutated. Pull-down fractions were analyzed for the presence of RNA-binding proteins by SDS-PAGE and silver staining (A) and shotgun tandem mass spectrometry (MS/MS). The proteins detected were represented with a Venn diagram reflecting the count of detected proteins per sample type (B upper panel) and a volcano plot with the ratio and statistical significances shown between the indicated probes (B lower panel). Vertical (magenta) and horizontal (green) dashed lines mark the thresholds for absolute fold change (≥±1.5) and p values (p ≤ 0.05). A continuous color scale is applied to each point in accordance to the estimated false discovery rate (FDR \<1%). Values corresponded to averages from three independent experiments.(C) Clustering of the paired sample ratio abundances for the identified hits.(D) A total of 106 candidates with a positive fold change (≥1.5) were analyzed in the database Panther (<http://pantherdb.org/>) for overrepresentation within four gene ontology categories performing a Fischer test with FDR correction. Bars represent the -log~10~-transformed corrected p value and are filled according to the calculated fold enrichment against the corresponding human genome background.

TRIM28 Negatively Regulates Human BOK Expression through Association with 3' UTR Contained U-Rich Elements {#sec2.5}
----------------------------------------------------------------------------------------------------------

To validate URE-binding candidates for their role in destabilizing *BOK* mRNA in living cells, we performed transfections of pooled endoribonuclease-prepared short interfering RNAs (esiRNA) in HEK293T cells stably expressing either the human *BOK* CDS-3'UTR or its URE mutated version (UREmut1-3). We evaluated several candidates belonging to the clusters defined in [Figure 4](#fig4){ref-type="fig"}C (*TRIM28, LSM5, SAFB2*) as well as one hit (*TIAL1*) that fell below the selection threshold (p value ≤ 0.05, fold change 3' UTR/3' UTR UREmut1-3 ≥ 1.5) but is a known regulator of mRNA stability, which served as a negative control ([@bib53], [@bib54]).

From this validation round, only knockdown of *TRIM28* produced a robust and statistically significant recovery of BOK protein levels in cells expressing exogenous BOK fused to the wild-type 3' UTR but not the URE1-3 mutated version ([Figure 5](#fig5){ref-type="fig"}A). TRIM28, also known as KAP1/TIF1-β, is a known co-repressor of gene expression at the chromatin level ([@bib24]). To strengthen our finding of TRIM28 acting at the mRNA level rather than at the genomic *BOK* locus, we transiently co-transfected *TRIM28*-specific esiRNA with *BOK*-*3'UTR* or *BOK-3'UTR(UREmut1-3)* expression plasmids into HEK293T cells and confirmed that the knockdown of TRIM28 only rescued BOK expression in those cells receiving the *BOK-3'UTR* construct, up to 70% compared with the control BOK-3'UTR(UREmut1-3) ([Figure 5](#fig5){ref-type="fig"}B). Furthermore, we corroborated the presence of endogenous TRIM28 protein in pull-down fractions from lysates prepared from the human cell lines HEK293T, HCT-116, and NCI-H1299 using biotinylated *CDS-3'UTR* RNA probe. However, the signal was reduced to non-specific binding (comparable with beads-only control) when using the *CDS-3'UTR(UREmut1-3)* probe, strengthening the evidence that TRIM28 indeed binds to the UREs present in the 3' UTR of BOK (see [Figures 5](#fig5){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"} for predicted RNA-binding motifs in TRIM28).Figure 5Validation of Selected BOK Negative Regulator Candidates(A) HEK293T cells stably expressing human BOK constructs CDS-3'UTR or CDS-3'UTR(UREmut1-3) were transfected with validated esiRNAs targeting the candidates *LSM5*, *TRIM28*, *SAFB2*, and *TIAL1*. The recovery of BOK protein levels was used to determine involvement of a candidate in the URE-mediated repression of BOK. Immunoblots shown are representative of three independent experiments, and the quantification (right panel) of the signal is presented as mean ± SD. Statistical differences were determined using a one-way ANOVA followed by a Tukey *post-hoc* test.(B) BOK recovery in HEK293T cells transiently co-transfected with human *BOK* CDS-3'UTR and esiRNA targeting TRIM28. The 3'UTR(UREmut1-3) construct was used as a 100% reference.(C) Demonstration of the specific recruitment of endogenous TRIM28 to the 3' UTR of human *BOK* in three independent cell lines using the indicated biotinylated synthetic probes (see [Figure S2](#mmc1){ref-type="supplementary-material"} for prediction of RNA binding motifs in TRIM28).(D) Transient overexpression of HA-tagged TRIM28 in the lung cancer cell line NCI-H1299 or the colon carcinoma cell line HCT-116 leads to downregulation of endogenous BOK without impacting on the levels of BAX or BAK. Quantitative immunoblots are representative of three independent experiments; data are presented as mean ± SD. Statistical differences were detected using an unpaired t test, comparing with the BOK levels obtained on the sample transfected with the empty vector. Downregulation of BOK by overexpressed HA-TRIM28 correlates with reduced *BOK* mRNA levels (means ±SD, N = 3).(E) Stable expression of HA-tagged TRIM28 in the lung cancer cell lines NCI-H1299 and LFX-289 leads to a reduction of endogenous BOK levels. See [Figure S3](#mmc1){ref-type="supplementary-material"}B for quantification.Significance levels, p \< 0.01\*\*, p \< 0.001\*\*\*, p \< 0.0001\*\*\*\*.

This functional link between BOK repression and TRIM28 could further be demonstrated by performing the opposite approach, in which we transiently overexpressed TRIM28 in the BOK-proficient colorectal cancer cell line HCT-116 or the NSCLC cell line NCI-H1299. As shown in [Figure 5](#fig5){ref-type="fig"}D, overexpression of HA-tagged TRIM28 resulted in a significant reduction of \>50% of endogenous BOK protein levels compared with the control vector. This modulation of endogenous BOK expression was independently confirmed in NCI-H1299 and LXF-289 lung cancer cell lines stably transduced with HA-TRIM28 ([Figures 5](#fig5){ref-type="fig"}E, [S3](#mmc1){ref-type="supplementary-material"}B, and S3C). Of note, this functional association with TRIM28 was specific for BOK within the pro-apoptotic multi-domain family members, since the expression levels of BAX and BAK remained unchanged under the same experimental conditions ([Figure 5](#fig5){ref-type="fig"}D). Given the high level of homology between human and mouse TRIM28, we transfected human TRIM28 into MEF and likewise found reduction in endogenous (mouse) BOK protein levels, supporting a similar mode of action of TRIM28-mediated BOK repression in mouse cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Taken together, these data demonstrate that TRIM28 recruitment to URE sites in the 3' UTR of human *BOK* mRNA results in a potent repression of BOK cellular abundance.

BOK and TRIM28 are Negatively Correlated in Selected Types of Cancer {#sec2.6}
--------------------------------------------------------------------

Our previous results demonstrated a negative impact of TRIM28 levels on BOK expression. We next sought to address whether this phenomenon could be detected in the publicly available Cancer Genome Atlas (TCGA) database. As previously reported, we found that elevated transcript levels of *TRIM28* constitute a risk factor in several cancer types, whereas *BOK* transcript levels mostly show an opposite trend (i.e., decreased in cancer), with the notable exception of adrenocortical cancer and skin cutaneous melanoma ([Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}). Simultaneous modeling of *BOK* and *TRIM28* levels using multiparametric Cox hazard ratio models in primary tumors derived from patients with kidney clear cell or papillary cell carcinoma as well as hepatocellular carcinoma indicated a significant reduction in the risk of death for patients with elevated *BOK* levels, which contrasts with the increased risk of death associated with high *TRIM28* expression ([Figure 6](#fig6){ref-type="fig"}A). Supporting these models, patients who simultaneously had *BOK* levels above and *TRIM28* levels below their respective population medians exhibited the best survival rate, in stark contrast to those patients belonging to the opposite strata ([Figure 6](#fig6){ref-type="fig"}B see [Table S2](#mmc3){ref-type="supplementary-material"}). Interestingly, in kidney malignancies, *TRIM28* and *BOK* expressions are negatively correlated in the patient stratum with the highest mortality rate, whereas it is less clear for liver and lung carcinomas ([Figure 6](#fig6){ref-type="fig"}C see [Table S2](#mmc3){ref-type="supplementary-material"}). Overall, these data strengthen the interrelationship between *TRIM28* and *BOK* expression indicating that, in these selected cancers, the negative correlation between *TRIM28* and *BOK* may potentially be of prognostic clinical value.Figure 6Potential Clinical Implications of the TRIM28 and BOK Interrelationship(A--C) (A) Multiparametric Cox hazard ratio modeling of *BOK* and *TRIM28* mRNA levels in several cancer types. Number of patients (N), 95% confidence interval of the hazard ratio function (HR 95% CI), significance (p value), and overall significance of the model (Model p value) are tabulated. Patients were classified according to their *BOK* and *TRIM28* levels with respect to each gene population median expression into two strata ("high"/"low") and further analyzed for overall survival (B) and correlation of the two genes within each strata (C). Differences in survival were detected with the log rank test, and correlations were determined using the Spearman\'s estimate. Significance levels, p \> 0.05^*ns*^, p \< 0.05\*, p \< 0.01\*\*, p \< 0.001\*\*\*. See [Table S2](#mmc3){ref-type="supplementary-material"} for original and full data.

Discussion {#sec3}
==========

BOK is emerging as a BCL-2 family member of increasing interest, both during development as well as in its role as a potential tumor suppressor or modulator of cancer behavior ([@bib8], [@bib31], [@bib40], [@bib44]). Owing to the pro-apoptotic response resulting from its accumulation, *BOK* expression seems to be tightly regulated at various levels. Here we expand this complexity by describing the existence of AU- and U-rich elements (ARE/URE) within the 3' UTR of mouse or human *BOK* mRNAs, respectively, both of which contribute to the negative regulation of BOK expression.

Our model provides an alternative yet non-excluding explanation to the previously described epigenetic and proteasomal regulation of BOK levels ([@bib37], [@bib40]). The existence of (A/U)RE could uncouple the transcription rate of the *BOK* genomic locus from its total protein concentration, explaining previously observed inconsistent correlations between BOK protein and mRNA levels in some mouse tissues and NSCLC biopsies ([@bib16], [@bib40]).

In our experimental setting, the (A/U)RE elements in the mouse and human BOK 3' UTRs exclusively acted as a negative regulators, which even worked for unrelated coding sequences, contrasting with the dual role of ARE sequences in both stabilization and destabilization of the mRNA of other genes, such as *BCL-2* ([@bib15], [@bib45]). This dominance of the *BOK* 3' UTR to suppress its transcript abundance and protein expression also suggests that the post-transcriptional control of *BOK* may dominate over its translational regulation, e.g. ribosome scanning or cap-(in)dependent translation, which is traditionally exerted by the 5' UTR region ([@bib32]).

In human cells, we showed that 3' UTR-dependent repression of *BOK* involves the recruitment of TRIM28 to the URE elements. This is a striking observation since all known repressing activities of TRIM28 occur at the chromatin level ([@bib6], [@bib34]), and more importantly, TRIM28 lacks classical nucleic-acid-binding motifs ([@bib28]). Considering this, TRIM28 is likely recruited as part of a multiprotein complex to the 3' UTR-URE sites rather than directly binding to the RNA. However, the latter possibility warrants further investigation since analysis of TRIM28 amino acid sequence with the Web tool catRAPIDsignature ([@bib36]) predicts multiple modules with potential RNA-binding activity ([Figure S2](#mmc1){ref-type="supplementary-material"}). Furthermore, experimental evidence from the Landthaler group, characterizing the transcript-bound proteome in HEK293T cells, detected TRIM28 in two of three mass spectrometry runs ([@bib3]), supporting the possibility of true mRNA binding of TRIM28. Regarding the underlying mechanism of mRNA degradation, it will be interesting to investigate whether TRIM28 requires its SUMO E3 ligase activity or not. Involvement of E3 ligase activity in such a context has been described for other RNA-binding E3 ligases, such as MEX-3C, which mediates a RING-dependent destabilization of MHC-I transcripts ([@bib7]).

The repression of BOK in human cells was TRIM28 dependent as demonstrated both by RNA interference and overexpression of TRIM28 in several independent cell lines. This mechanism seems peculiar for *BOK*, since our mass spectrometry data showed absence of *ELAVL1* and tristetraprolin (*TTP*), two of the most common mediators of ARE-based RNA decay in the human transcriptome ([@bib2]). Another feature of TRIM28-mediated regulation seems to be the specificity for *BOK* over its pro-apoptotic multidomain relatives *BAX* and *BAK*. This might result from the type, abundance, and position of the predicted URE sites in the respective 3' UTRs of these particular genes, which at the same time greatly diverges from the best studied ARE-regulated protein of the whole family, the *BCL-2* gene ([Figure S1](#mmc1){ref-type="supplementary-material"}).

Our proteomic approach combined with independent protein pull-downs using biotinylated RNA probes undoubtedly placed TRIM28 at the mRNA level; separating its known role at the chromatin from our discovered function at the mRNA level was challenging. Therefore, we performed our assays using transient transfections and collecting the samples within a short temporal window, as well as included some assays using stable transfections. These assays indicated that relatively high levels of TRIM28 may be required to repress *BOK* mRNA. It is further possible that TRIM28 may affect BOK protein stability directly (e.g., in LFX-289 cells), and further investigation in that direction is needed. The transient approach allowed us to minimize the likelihood of chromosomal integration of the transfected BOK expression constructs, increasing the chance of a transcript-based regulatory mechanism.

Our results provide a potential value of the TRIM28-dependent, URE-mediated decay of *BOK* mRNA in certain cancers, particularly in subtypes of kidney and lung carcinomas, considering their inverse correlation in the stratum of patients with the worst overall survival and/or risk of event. It should be noted, however, that, as a limitation of these results, such an inverse correlation was only shown at the mRNA level but not yet interrogated at the protein level. *TRIM28* is increased in several cancerous malignancies, and increased TRIM28 is a poor prognosis factor in early-stage NSCLC ([@bib35]), glioma ([@bib43]), and colorectal cancer ([@bib20]). Furthermore, TRIM28 increases the expression of the ATP-binding cassette genes ABCG2 and ABCB1, thus contributing to chemoresistance to paclitaxel and cisplatin of epithelial ovarian cancer cells ([@bib26]). On the contrary, pro-apoptotic *BOK* is currently discussed as a potential tumor suppressor gene, since its genomic locus is deleted across various cancers ([@bib4]) and elevated levels of this protein are associated with enhanced overall survival of patients with lymph-node-positive lung cancer ([@bib40]). It is currently not clear whether TRIM28-mediated repression of BOK levels primarily affects apoptotic responses or whether recently described "non-apoptotic" roles of BOK need to be considered as well ([@bib13], [@bib30], [@bib40], [@bib44]). Along that line, a molecular process potentially linking TRIM28 and BOK could be EMT. Knockdown of TRIM28 was shown to impair EMT in ovarian cancer cells by upregulation of E-cadherin (CHD1) and reduction of vimentin (*VIM*) and N-cadherin (CDH2) ([@bib14]). Along the same line, Chen and colleagues reported that, in NSCLCs, TGFβ-induced EMT is dependent on induction of TRIM28, strongly suggesting that TRIM28 contributes to EMT in NSCLC ([@bib9]). TRIM28 was further shown to promote EMT and metastasis in breast cancer ([@bib52]). Strikingly these phenotypes reported for downregulation or overexpression of TRIM28 with regards to EMT are inversely mimicked by BOK, as we have recently shown for NSCLC cells that overexpression of BOK antagonizes TGFβ-induced EMT ([@bib40]), thereby further underlining the connection and opposing functions of TRIM28 and BOK in a cancer context.

In summary, we have identified a post-transcriptional negative regulation of BOK expression through association of TRIM28 with distinct URE present in the 3' UTR of the BOK transcript, resulting in destabilization and decay of the latter. This mechanism seems to rather specifically affect BOK, while sparing other pro-apoptotic multi-domain BCL-2 family members. Future efforts should focus on integrating this regulatory mechanism into the various (patho)physiological functions that have been described for BOK, in particular corroborating its relevance to cancer biology and its potential use by cancer cells to evade current chemotherapeutic regimens and/or to promote malignant transformation, including metastasis.

Limitations of the Study {#sec3.1}
------------------------

Recent advances in elucidating the role of BOK in health and disease suggest that its abundance could be a critical factor to the cellular fate. Nevertheless, we lack comprehensive understanding of how BOK levels are regulated. Our work provides another layer of BOK regulation, involving the description of destabilizing (AU/U)-rich elements in the 3' UTR of its mRNA. We currently do not know if and how strongly these regulatory elements contribute to physiology in development or in adult life. One of the destabilizing factors identified to associate with the U-rich elements of human *BOK* 3' UTR is TRIM28. It is not clear whether TRIM28 directly binds to mRNA or indirectly as part of a macromolecular protein complex and through which mechanism TRIM28 induces mRNA destabilization.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1--S5Table S1. Results from Shotgun Mass Spectrometry Analysis Using mRNA Biotinylated ProbesDetails the identified proteins, peptide numbers, principal-component analysis, clustered analysis, t test, and FDR correction for each independent replicate pulled down with the BOK-3' UTR wild-type or URE-mutated RNA probes.Table S2. Clinical and Expression Matrix Used for Cox Regression, Survival and Correlation AnalysisDataset containing TRIM28 and BOK gene expression matched to clinical parameters in 33 cancer types by patient ID following the TCGA nomenclature. Includes detailed description of the original data source as well as the manipulations performed in this work to stratified patients according to the selected gene expression.
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